EN
Home/Answers/GLP-1s and cholesterol
ALLAll countries Side effects and safety

Do tirzepatide and semaglutide raise or lower cholesterol?

What we checked14 sources, each one opened and linked to the sentence it supportsLast checked Nov 16, 2026 · Next review due Nov 16, 2027 · How we write
The short answer

On average, tirzepatide (Zepbound, Mounjaro) and semaglutide (Wegovy, Ozempic) lowered cholesterol slightly in weight trials, the US labels show. LDL (“bad” cholesterol) fell 7.1% on tirzepatide 15 mg against 1.7% on placebo. It fell 2.5% on semaglutide 2.4 mg, against a 1.3% rise on placebo. Triglycerides fell more. A small diet study found cholesterol can rise temporarily during weight loss.

What happened to cholesterol in the weight trials?

In the main weight trials, LDL cholesterol fell slightly and triglycerides fell more on both medicines than on a dummy injection (placebo).1,2

Tirzepatide, SURMOUNT-1. Over 72 weeks on Zepbound 15 mg, LDL fell 7.1%, against 1.7% on placebo. Triglycerides (a type of blood fat) fell 29.1%, against 5.6%. HDL (“good” cholesterol) rose 8.0%, against a 0.7% fall.1

Semaglutide, STEP 1. Over 68 weeks on Wegovy 2.4 mg, LDL fell 2.5%, against a 1.3% rise on placebo. Triglycerides fell 21.9%, against 7.3%, and HDL rose 5.2%, against 1.4%.2 In SELECT, a heart trial, LDL was 5.3% lower at 2 years on Wegovy, against 3.1% on placebo.2

Against each other. The UK Mounjaro label reports a 40-week diabetes trial against semaglutide 1 mg. Triglycerides fell 19% to 25% on tirzepatide, against 12%.10

These were extra findings, which both US labels say were not tested as strictly as weight loss.1,2

Can cholesterol rise while you are losing weight?

On tirzepatide, average total and LDL cholesterol fell during weight loss, while HDL dipped. A small diet study saw a temporary rise.1,5

In SURMOUNT-4, people took tirzepatide openly for 36 weeks before some were switched to placebo. Over those 36 weeks, average LDL fell by 1.9 mg/dL and triglycerides by 40.4 mg/dL. HDL fell by 2.7 mg/dL.1

Over the next year, HDL rose again. This happened both in people who stayed on tirzepatide and in those switched to placebo.1 The label's tables give group averages, so they do not show how many people's levels went up.1

A 1991 study followed 6 women on very-low-calorie diets, without GLP-1 medicines. Their cholesterol fell from 5.49 to 3.62 mmol/L in the first 1 to 2 months. It then rose to 5.95 mmol/L as weight loss went on.5 The authors suggested cholesterol released from fat stores, and the rise faded once weight loss stopped.5

Is lowering cholesterol a labelled use?

No. The US Zepbound label lists weight and sleep apnoea uses. The US Wegovy label lists weight, heart-risk and other uses, but not cholesterol.1,2

Weight loss on these medicines carries a gallbladder risk. In two Zepbound weight trials, an inflamed gallbladder (cholecystitis) affected 0.7%, against 0.2% on placebo. The label links gallbladder events with weight loss.1 The US Wegovy label says large or rapid weight loss can raise the risk of gallbladder disease.2

RisksThe risks, in brief
  • Gallbladder problems were more common on Zepbound than on placebo, and the label links them with weight loss.1
  • Inflamed pancreas (pancreatitis) is a labelled risk. Its sign is severe stomach pain that will not go away, sometimes spreading to the back.1,2
GLP-1 side effects guide (pick your country in “In your country” below) →

What do people on GLP-1 medicines report about cholesterol?

From public patient forums: 43 Reddit threads in r/Zepbound, r/Mounjaro, r/Semaglutide, r/Ozempic, r/mounjarouk and r/Wegovy, read October 2025 to October 2026. Personal reports, not medical evidence.

What people describe

  • Label says otherwise Most describe cholesterol or triglycerides getting worse while weight was coming off. In the trials behind the US labels, average LDL and triglycerides fell. The tables do not show how many people’s levels rose.1,2
  • Matches a small study Many say their levels settled once their weight was stable. A small diet study found a rise in cholesterol faded once weight loss stopped.5
  • Matches the label Several say HDL dropped during weight loss and recovered on later tests. In SURMOUNT-4, average HDL fell over 36 weeks of weight loss, then rose again.1
  • Matches the label Several had gallbladder problems or gallstones around the same time. The US Zepbound label links gallbladder events with weight loss.1

Advice people share

  • Not studied Most suggest retesting once weight has been stable for a few months, rather than acting on one result. We found no study of when to retest on these medicines.
  • Matches the NHS Many suggest adding unsaturated fats such as olive oil, nuts or oily fish, and several suggest cutting saturated fat. The NHS gives the same food advice for lowering cholesterol.6
  • The NHS says otherwise Several posts dismiss cholesterol readings or describe stopping a prescribed statin alone. The NHS says stopping statins may affect cholesterol levels.7

In your country

The trial results are the same everywhere. Which cholesterol results each country's label prints differs.

Australia

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: none (Wegovy pill treated as not approved). Semaglutide tablets, diabetes: Rybelsus approved; whether supplied not confirmed.

Label: The Australian Mounjaro label gives SURMOUNT-1 results for all doses combined. LDL fell 6.8%, against 0.9% on placebo, and triglycerides fell 27.6%, against 6.3%.13 The Australian Wegovy label gives the same STEP 1 results as above.14

Emergency number: 000

Side effects and risks in Australia

Canada

Sold as: Tirzepatide: Mounjaro, Mounjaro KwikPen, Zepbound. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic; Semaglutide Injection (Dr. Reddy’s; shortage reported Jul 2026, lots recalled Aug 2026); Apo-Semaglutide (one lot recalled Aug 2026). Semaglutide tablets, weight: none (no oral Wegovy in Health Canada’s drug database). Semaglutide tablets, diabetes: Rybelsus. Semaglutide approved but not marketed: Sevmia, Poviztra, Plosbrio, Aspen-Semaglutide, Semaglutide Injection (Aspen), Sandoz Semaglutide.

Label: Health Canada's Wegovy monograph gives the same STEP 1 results, in mmol/L.9 Health Canada’s Zepbound monograph gives SURMOUNT-1 results for all doses combined. Triglycerides fell 24.8%, against 5.6% on placebo, and HDL rose 8.0%, against a 0.7% fall. It gives no LDL figure.11

Emergency number: 911

Side effects and risks in Canada

France

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: none (Wegovy pill not sold in France). Semaglutide tablets, diabetes: none found (Rybelsus not in France’s medicines database).

Label: The EU Mounjaro label gives SURMOUNT-1 results for all doses combined: triglycerides fell 27.6% and HDL rose 7.9%. It gives no LDL figure.3 The EU Wegovy label gives no STEP 1 cholesterol results.4

Emergency number: 15 or 112

Effets indésirables et risques (en français)

Germany

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy, including 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy Tablette. Semaglutide tablets, diabetes: Rybelsus.

Label: The EU Mounjaro label gives SURMOUNT-1 results for all doses combined: triglycerides fell 27.6% and HDL rose 7.9%. It gives no LDL figure.3 The EU Wegovy label gives no STEP 1 cholesterol results.4

Emergency number: 112

Nebenwirkungen und Risiken (auf Deutsch)

India

Sold as: Tirzepatide: Mounjaro, Yurpeak. Semaglutide injection, weight: Wegovy; Poviztra; Noveltreat. Semaglutide injection, diabetes: Ozempic; Obeda (Dr Reddy’s; recalled Jul 2026 over an active-ingredient impurity; on 23 Oct 2026 the company said it planned to relaunch in Nov; resumption not confirmed at 8 Nov 2026; distributors told Reuters it may be discontinued); Sematrinity; GLIPIQ; Semalix (batches recalled Jul 2026); Semanat; Semafull. Semaglutide injection, diabetes and weight: Semaglyn; Mashema; Alterme; Semasize; Obesema; Hepaglide. Semaglutide, diabetes and weight (form not confirmed): Obeda Pro; Obeda Plus (Dr Reddy’s, made by Hetero Labs; in the market from late Jul 2026). Semaglutide injection, use not confirmed: Semanext; Livarise; Sundae. Semaglutide, form and use not confirmed: Samakind; Usema (batches recalled). Semaglutide tablets, weight: not confirmed. Semaglutide tablets, diabetes: Rybelsus; Sembolic; Obeda (tablets not part of the Jul 2026 recall).

Label: We could not open an Indian label, so this page relies on the US and EU labels.

Emergency number: 112

Side effects and risks in India

Saudi Arabia

Sold as: Tirzepatide: Mounjaro, Mounjaro KwikPen. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic; Tasylev; Lugyda; Glucentra. Semaglutide tablets, weight: none (Wegovy pill not registered). Semaglutide tablets, diabetes: Rybelsus.

Label: We could not open a Saudi label, so this page relies on the US and EU labels.

Emergency number: 997 or 911

Side effects and risks in Saudi Arabia

United Arab Emirates

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy pill. Semaglutide tablets, diabetes: Rybelsus.

Label: We could not open a UAE label, so this page relies on the US and EU labels.

Emergency number: 998 for an ambulance, or 999

Side effects and risks in the UAE

United Kingdom

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy, including 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy tablets (authorised 11 Jun 2026; retail sale not confirmed). Semaglutide tablets, diabetes: Rybelsus.

Label: The UK Mounjaro label gives its own SURMOUNT-1 figures by dose. On 15 mg, LDL fell 8.6%, against 0.9% on placebo. Triglycerides fell 24%, 27% and 31% on 5, 10 and 15 mg, against 6% on placebo.10 The UK Wegovy label gives SELECT’s cholesterol results, but no STEP 1 figures.12

Emergency number: 999

Side effects and risks in the UK

United States

Sold as: Tirzepatide: Zepbound, Mounjaro. Semaglutide injection, weight: Wegovy, including Wegovy HD 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy pill. Semaglutide tablets, diabetes: Ozempic tablets; Rybelsus (being discontinued).

Label: The answer above applies.

Emergency number: 911

Side effects and risks in the US

Get help now: call your local emergency number for chest pressure, tightness or fullness lasting more than a few minutes, or pain spreading to the shoulders, neck, jaw, arms or back. Shortness of breath, nausea, light-headedness or cold sweats can also signal a heart attack. Call an ambulance rather than driving yourself.8 Emergency numbers: 911 in the US and Canada, 999 in the UK, 998 or 999 in the UAE, 000 in Australia, 112 in India and Germany, 15 or 112 in France, 997 or 911 in Saudi Arabia.

Contact your prescriber or a doctor right away if you have severe stomach pain that will not go away, sometimes spreading to your back, or upper stomach pain with fever, yellow skin or eyes, or clay-coloured stools.2

Read the full picture

Related questions

Did this answer your question?

Sources

  1. Eli Lilly. Zepbound (tirzepatide) US prescribing information, sections 1, 5.4, 5.5 and 14.1 (SURMOUNT-1, Table 3; SURMOUNT-4, Table 7) (US label). Lilly
  2. Novo Nordisk. Wegovy (semaglutide) US prescribing information, sections 1, 14.1 (SELECT, Table 7), 14.2 (STEP 1, Table 13) and 17 (US label). DailyMed
  3. European Medicines Agency. Mounjaro (tirzepatide) summary of product characteristics, section 5.1 (EU SmPC). PDF
  4. European Medicines Agency. Wegovy (semaglutide) summary of product characteristics, section 5.1 (EU SmPC). PDF
  5. Phinney SD, Tang AB, Waggoner CR, Tezanos-Pinto RG, Davis PA. The transient hypercholesterolemia of major weight loss. Am J Clin Nutr 1991;53(6):1404–10. DOI · PMID 2035468
  6. NHS. How to lower your cholesterol. Reviewed 13 March 2026. NHS
  7. NHS. Statins. Reviewed 5 May 2026. NHS
  8. American College of Emergency Physicians. Emergency physicians explain how to recognize signs of a heart attack. 20 February 2026. ACEP
  9. Novo Nordisk Canada. Wegovy (semaglutide injection) Product Monograph, clinical trials section (STEP 1) (Health Canada label). PDF
  10. Eli Lilly. Mounjaro KwikPen summary of product characteristics, section 5.1 (UK SmPC, emc). emc
  11. Eli Lilly Canada. Zepbound (tirzepatide injection) Product Monograph (Health Canada label). PDF
  12. Novo Nordisk. Wegovy 2.4 mg FlexTouch summary of product characteristics, section 5.1 (UK SmPC, emc). emc
  13. Eli Lilly Australia. Mounjaro (tirzepatide) Australian product information, clinical trials (SURMOUNT-1) (Australian PI). PDF
  14. Novo Nordisk. Wegovy (semaglutide) Australian product information, clinical trials (STEP 1, Table 7) (Australian PI). medsinfo

Last checked Nov 16, 2026 · Next review due Nov 16, 2027 · Report an error

How this answer was made. Written by the GLP Guidebook team from the sources above, all checked on Nov 16, 2026. The “What people report” section summarises public patient forum posts we read; it is not medical evidence, and we never pass on advice that goes against the label. It’s general information, not medical advice. Talk to a doctor, pharmacist or other licensed prescriber before starting, stopping or changing any medicine. In an emergency, call your local emergency number. How we write